Antibodies targeting PD-1 (programmed cell death 1, also known as PDCD1) and PD-L1 (PDCD1 ligand 1, also known as B7H1 and CD274) are promising strategies in many cancer types, including colorectal cancer. Here, PDCD1 is linked to colorectal cancer.